Titan Pharmaceuticals, Inc. announced that the pursuant to the Purchase Agreement, David Lazar and Peter Chasey submitted their resignations from the Company?s Board of Directors, which resignations are effective immediately upon the appointment of two replacement directors to fill the vacancies. The resignations were not the result of any disagreements with the Company relating to the Company?s operations, policies or practices. Mr. Lazar will remain with the Company as Chief Executive Officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.9 USD | +1.17% | +0.29% | -16.36% |
04-01 | Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
01-26 | Titan Pharmaceuticals Regains Compliance With Nasdaq Listing Rule | MT |
1st Jan change | Capi. | |
---|---|---|
-16.36% | 6.31M | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- TTNP Stock
- News Titan Pharmaceuticals, Inc.
- Titan Pharmaceuticals, Inc. Announces Board Resignations